| |
| |
|
| Insider
Information: |
Shanmugam Muthusamy |
| Relationship: |
HEAD OF R&D, COO-NOVIT... |
| City: |
Baudette |
| State: |
MN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
68,652 |
|
|
Indirect Shares
|
787,620 |
|
|
| Direct
Value |
$4,566,731 |
|
|
|
Indirect Value
|
$52,392,482 |
|
|
| Total
Shares |
856,272 |
|
|
| Total
Value |
$56,959,213 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
ANI Pharmaceuticals Inc |
ANIP |
HEAD OF R&D, COO-NOVIT... |
2024-04-19 |
68,652 |
2024-04-19 |
787,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-19 |
4 |
AS |
$65.17 |
$1,095,443 |
I/I |
(16,809) |
782,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-18 |
4 |
AS |
$64.98 |
$677,287 |
I/I |
(10,423) |
799,429 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-17 |
4 |
AS |
$65.40 |
$622,608 |
I/I |
(9,520) |
809,852 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-16 |
4 |
AS |
$66.20 |
$386,211 |
I/I |
(5,834) |
819,372 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-15 |
4 |
AS |
$66.33 |
$491,771 |
I/I |
(7,414) |
825,206 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-08 |
4 |
AS |
$67.17 |
$671,700 |
I/I |
(10,000) |
832,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-07 |
4 |
AS |
$66.35 |
$1,000,890 |
I/I |
(15,085) |
842,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-06 |
4 |
AS |
$65.47 |
$970,396 |
I/I |
(14,822) |
857,705 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-05 |
4 |
AS |
$65.35 |
$659,578 |
I/I |
(10,093) |
872,527 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-02-29 |
4 |
D |
$67.67 |
$75,926 |
D/D |
(1,122) |
68,652 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,367 |
69,774 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-23 |
4 |
AS |
$56.44 |
$846,600 |
I/I |
(15,000) |
882,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-22 |
4 |
AS |
$55.95 |
$318,467 |
I/I |
(5,692) |
897,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-19 |
4 |
AS |
$55.57 |
$251,399 |
I/I |
(4,524) |
903,312 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-18 |
4 |
AS |
$55.30 |
$541,055 |
I/I |
(9,784) |
907,836 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-17 |
4 |
AS |
$55.11 |
$551,100 |
I/I |
(10,000) |
917,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-16 |
4 |
AS |
$55.63 |
$278,150 |
I/I |
(5,000) |
927,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-12-19 |
4 |
AS |
$52.65 |
$1,316,250 |
I/I |
(25,000) |
932,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-12-18 |
4 |
AS |
$52.44 |
$683,083 |
I/I |
(13,026) |
957,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-12-15 |
4 |
AS |
$52.44 |
$627,917 |
I/I |
(11,974) |
970,646 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-17 |
4 |
AS |
$51.00 |
$663,000 |
I/I |
(13,000) |
982,620 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-16 |
4/A |
AS |
$51.66 |
$333,104 |
I/I |
(6,448) |
995,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-16 |
4 |
AS |
$51.66 |
$333,104 |
I/I |
(6,448) |
996,430 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-15 |
4 |
AS |
$53.64 |
$410,185 |
I/I |
(7,647) |
1,002,878 |
0 |
% |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-15 |
4/A |
AS |
$53.64 |
$410,185 |
I/I |
(7,647) |
1,002,068 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
